Insights On Enterprise Solutions

  1. The Hidden Challenges Of ADC Manufacturing - And How To Overcome Them 1/30/2026

    ADC manufacturing requires specialized expertise, single‑use systems, precise filtration, aseptic filling, and integrated lyophilization to ensure stability, safety, and consistent clinical‑grade production.

  2. Construct Viability: A Hidden Challenge In Viral Vector Manufacturing 1/30/2026

    Rapid, low‑cost checks can catch construct issues that limit vector manufacturing, enabling early fixes to improve titers, avoid delays, and accelerate gene therapy programs.

  3. Viral Clearance Strategies For Monoclonal Antibodies And Proteins 1/30/2026

    Guidance on designing viral clearance studies using regulatory-aligned, risk‑based strategies, optimized assays, and real case examples for safe, efficient biologics development.

  4. How Can Data Translation Challenges In CRO Partnerships Be Overcome? 1/29/2026

    Biopharma–CRO partnerships often struggle with fragmented communication. Gain insight into how streamlined, automated workflows improve transparency, data quality, and operational speed.

  5. Scaling Cell And Gene Therapies: Crossing The Inflection Point 1/29/2026

    Progress in cell and gene therapy hinges on aligning therapeutic design with scalable, efficient manufacturing to improve accessibility, reliability, and real‑world feasibility across advanced modalities.

  6. Building A Unique Portfolio Of Therapeutic Base Editors 1/29/2026

    Stepwise engineering produces ABEs with tunable potency, precision, PAM range, and context specificity, enabling robust and targeted genome editing across diverse therapeutic sites.

  7. Boosting Base Editors For Genomic Medicine 1/29/2026

    Advanced CRISPR and base‑editing technologies are engineered to enhance potency, specificity, PAM flexibility, and safety, enabling more precise and efficient development of genetic medicines.

  8. Solving Four Challenges In Development With Scale-Out Manufacturing 1/28/2026

    Scale-out biomanufacturing enhances flexibility, speeds timelines, lowers risk, and enables efficient parallel production for scalable, resilient biologics and advanced therapies.

  9. Simplified Harvest And Media Exchange In Cell Therapy 1/28/2026

    Scale-up often introduces shear stress and process variability. Learn how low-shear, single-use technology stabilizes media exchange and harvest, ensuring consistent cell quality and predictable performance.

  10. From Fed-Batch To Continuous: How Perfusion Enables Smarter Biologics Production 1/28/2026

    Growing biologics demand is driving interest in perfusion culture as a complementary manufacturing strategy that enables continuous nutrient control, higher productivity, and performance when paired with fed-batch processes.